A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
Instituto de Biomedicina de Sevilla · Hospital Universitario Virgen del Rocío · +4 more institutions
Abstract
•There are no approved therapies for fatty liver disease.•Dual glucagon/glucagon-like peptide-1 receptor agonism may be beneficial.•Efinopegdutide (dual agonist) improved liver fat content compared with semaglutide.•Efinopegdutide’s tolerability profile was similar to that of semaglutide.•Efinopegdutide may be an effective treatment for fatty liver disease. Background & AimsThis study assessed the effects of the glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist efinopegdutide relative to the selective GLP-1 receptor agonist semaglutide on liver fat content (LFC) in patients with non-alcoholic fatty liver disease (NAFLD).MethodsThis was a phase IIa, randomized, active-comparator-controlled,…
Citation impact
- FWCI
- 37.75
- Percentile
- 100%
- References
- 27
Authors
77- MRManuel Romero‐Gómez
Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Universidad de Sevilla
- ELEric Lawitz
The University of Texas at San Antonio Health Science Center, Texas Liver Institute
- RRR. Ravi Shankar
Merck & Co., Inc., Rahway, NJ, USA (United States)
- ECEirum Chaudhri
Merck & Co., Inc., Rahway, NJ, USA (United States)
- JLJie Liu
Merck & Co., Inc., Rahway, NJ, USA (United States)
Topics & keywords
- Fatty liver
- Alcoholic liver disease
- Comparator
- Medicine
- Disease
- Internal medicine
- Gastroenterology
- Physics
- Good health and well-being